BAIJIN LIFE SCI (01466) announced that its indirect wholly-owned subsidiary, Beijing Baijin Biotechnology Co., Ltd. (Beijing Baijin), has entered into a strategic cooperation framework agreement with Fuyao Yuanqi Biotechnology Co., Ltd. (Fuyao Yuanqi) concerning strategic collaboration in the field of clinical cell therapy. Under the framework agreement, Beijing Baijin will be responsible for the research and development, production, quality control, and global supply chain support of products within the scope of the collaboration, and will establish a unified compliance standard system. Fuyao Yuanqi will leverage its expert team, patent portfolio, and market operation capabilities to facilitate the direct integration of Beijing Baijin's technological production capacity with Fuyao Yuanqi's technical expertise, thereby completing a clinical translation cycle from "capability" to "implementation." Fuyao Yuanqi's core technologies originate from the commercialization of scientific research achievements from leading higher education and research institutions in China. It has established specialized technology transfer cooperation arrangements and secured exclusive licensing for relevant patents. Fuyao Yuanqi also possesses experience in clinical cell drug research filing. The board of directors believes that the collaboration is expected to enable consumers to make more informed decisions when choosing cell-related products and services by referring to clearer qualification and certification standards, thereby reducing the risk of blind trial-and-error in the market. The board further noted that with the "Regulations on the Clinical Research and Clinical Translation Application of New Biomedical Technologies" (State Council Decree No. 818) taking effect on May 1, 2026, the domestic cell industry is anticipated to enter a more standardized phase, differing from the previous market environment characterized by "concept first, standards lagging." The board considers that enterprises lacking technical verification and clinical filing qualifications may face increasing market pressure, while those with technological accumulation, patent portfolios, and clinical research capabilities are likely better positioned to advance from technological development to industrial application.